PCSK9 Forum is made possible thanks to support from AstraZeneca, LIB Therapeutics, Novartis and Sanofi, all of whom have no influence or control of editorial content. More information is available here »

Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

Anne Tybjaerg-Hansen Articles

Genetics of Lp(a) and CVD

Genetics of Lp(a) and CVD

Reports from the 9th Closed Expert Meeting of the PCSK9 Education and Research Forum Professor Anne Tybjærg-Hansen 

read more »
Posted on 3 December 2018 | Posted by Anne Tybjaerg-Hansen | Posted in Webcasts, 9th Closed Scientific Expert Meeting of the Editorial Board
PlayLoss of function mutations in PCSK9: the trigger for therapeutic development

Loss of function mutations in PCSK9: the trigger for therapeutic development

Studies of mutations of PCSK9 function have identified a new therapeutic target for reducing very high levels of low density lipoprotein cholesterol (LDL-C). Professor Anne Tybjaerg-Hansen describes this opportunity.

read more »
Posted on 1 December 2014 | Posted by Anne Tybjaerg-Hansen | Posted in Videos
Mechanistic insights from PCSK9 LOF mutations

Mechanistic insights from PCSK9 LOF mutations

Mechanistic insights from PCSK9 LOF mutations with a particular focus on data from the Copenhagen studies, were discussed by Professor Anne Tybjaerg-Hansen, Rigshospitalet, Copenhagen University Hospital, and University of Copenhagen, Denmark. Seminal studies showed that carriage of LOF mutations was associated reduction in LDL cholesterol…

read more »
Posted on 30 September 2014 | Posted by Anne Tybjaerg-Hansen | Posted in Article Archive, Webcasts, Inaugural Closed Scientific Expert Meeting of the Editorial Board, Inaugural Closed Expert Meeting of the Editorial Board 2014

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.
Educational Partners and Supporters
AstraZeneca

AstraZeneca has provided a grant towards this independent project and has had no involvement in its creation or organisation

LIB Therapeutics

Novartis

Sanofi

© Copyright 2025 PCSK9 Forum. All rights reserved